Puzo, Martín https://orcid.org/0000-0002-5048-4846
Calvo-Perez, Pilar
Bartol-Puyal, Francisco https://orcid.org/0000-0002-4476-6003
Sanchez-Monroy, Jorge https://orcid.org/0000-0001-5743-1520
Martin-Pinardel, Ruben
Parrado-Carrillo, Alba
Moll-Udina, Aina
Bernal-Morales, Carolina https://orcid.org/0000-0001-5469-3963
Sanchez-Vela, Laura
Sararols-Ramsay, Laura
Garay-Aramburu, Gonzaga https://orcid.org/0000-0001-5255-8426
Arruabarrena, Carolina https://orcid.org/0000-0002-5312-8900
García-Arumí, José
Abraldes, Maximino
Ruiz-Moreno, José María https://orcid.org/0000-0001-9636-0788
Valldeperas, Xavier
Velázquez-Villoria, Daniel https://orcid.org/0000-0002-8677-6859
Escobar-Barranco, José Juan
Gallego-Pinazo, Roberto
Figueroa, Marta S.
Figueras-Roca, Marc
Barthelmes, Daniel
Gillies, Mark C. https://orcid.org/0000-0001-8580-0274
Casaroli-Marano, Ricardo P.
Zarranz-Ventura, Javier https://orcid.org/0000-0003-2338-8143
,
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Bayer
Novartis Farmacéutica
Article History
Received: 22 January 2024
Revised: 7 August 2024
Accepted: 3 September 2024
First Online: 21 September 2024
Competing interests
: JZV, PCP, and MCG receive funding and consult for Novartis Pharmaceuticals and Bayer. JZV is a member of the Eye editorial board.